STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Clinical trials for STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare liver cancer: Triple-Drug combo targets unresectable tumors
Disease control Recruiting nowThis early-phase study tests a combination of three drugs—nivolumab (an immunotherapy), fluorouracil (chemotherapy), and interferon alpha-2b (an immune stimulant)—in people with a rare type of liver cancer called fibrolamellar carcinoma that cannot be surgically removed. The goal…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New drug AU409 enters first human tests for tough liver cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called AU409 in 36 adults with advanced liver cancer or solid tumors that have spread to the liver. The main goals are to find the safest dose and check for side effects. Researchers also look for early signs that the drug might shrink or s…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New combo therapy for unresectable liver cancer shows promise in early trial
Disease control Recruiting nowThis study is for people with advanced liver cancer that cannot be removed by surgery. It tests a treatment that uses the patient's own immune cells, trained in a lab to attack the tumor, combined with immunotherapy drugs and a pneumonia vaccine, all given after high-dose radiati…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
Custom-Made vaccine plus immunotherapy shows promise for advanced cancers
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps control t…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
Radiation plus immunotherapy may boost survival in advanced liver cancer
Disease control Recruiting nowThis study is for people with advanced liver cancer that has spread to nearby blood vessels. It compares standard immunotherapy drugs alone versus immunotherapy plus targeted radiation (SBRT). The goal is to see if adding radiation helps people live longer. About 226 adults will …
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Electric field device joins forces with cancer drugs in early trial
Disease control Recruiting nowThis early-phase study tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or a chemo-immunotherapy pair (nab-paclitaxel and atezolizumab) in people with advanced solid tumors in the abdomen or chest. The goal is to find …
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC
-
Could a common painkiller boost immunotherapy for liver cancer?
Disease control Recruiting nowThis study tests whether adding the pain reliever celecoxib to two immunotherapy drugs (durvalumab and tremelimumab) can help treat advanced liver cancer that has spread. About 39 adults with liver cancer that has not responded to prior treatment will receive this combination. Th…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
Can radiation kickstart the immune system against stubborn GI cancers?
Disease control Recruiting nowThis study is for people with advanced gastrointestinal cancers that are growing despite immunotherapy. Researchers want to see if adding targeted radiation to one tumor can help the immune system attack other tumors throughout the body. About 28 participants will receive radiati…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 12, 2026 12:04 UTC
-
New drug combo targets Hard-to-Treat liver cancer gene
Disease control Recruiting nowThis study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific change in the β-catenin gene. The goal is to find the best dose and see if the combination can shrink tumors or slow the cancer's growth. About 92 adults w…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
Radiation plus immunotherapy: new hope for advanced liver cancer?
Disease control Recruiting nowThis study tests whether giving two immunotherapy drugs (durvalumab with or without tremelimumab) after a short course of radiation can help control advanced liver cancer that has spread. About 21 adults whose cancer has worsened despite prior treatment will receive radiation fol…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Mary Feng, MD • Aim: Disease control
Last updated Jun 10, 2026 13:26 UTC
-
Liver cancer patients get second chance with new combo therapy
Disease control Recruiting nowThis study tests whether adding an immunotherapy drug (atezolizumab) to a standard targeted therapy (cabozantinib or lenvatinib) works better than the targeted therapy alone for people with advanced liver cancer that cannot be surgically removed. Participants must have already re…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jun 08, 2026 13:04 UTC
-
Morning or afternoon? new study tests best time for cancer immunotherapy
Symptom relief Recruiting nowThis study looks at whether getting immunotherapy in the morning or afternoon makes it work better for people with advanced or spreading solid tumors. The body's internal clock (circadian rhythm) may affect how the immune system responds. Researchers will compare progression-free…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated Jun 11, 2026 12:12 UTC
-
Scientists peek inside tumors during surgery to see how they behave
Knowledge-focused Recruiting nowThis study uses a special microscope to look at blood vessels inside solid tumors while patients are having surgery. The goal is to understand how these vessels work, which could help doctors decide if a patient's tumor is likely to respond to certain treatments. About 85 adults …
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:08 UTC